TABLE 3.
Study, year | Cardiac population | Sample (n) | Intervention | Duration (weeks) | Time of follow-up (months) | Daily dose (mg) | Biochemical validation |
---|---|---|---|---|---|---|---|
Tonstad et al (30), 2003 | CVD (had to have at least one of the following conditions: MI >3 months previously, an interventional cardiac procedure, stable angina, PVD or CHF) | 626 | Bupropion | 7 | 12 | 300* | Expired CO |
Joseph et al (32), 1996 | CVD (history of MI, CABG, angioplasty, stenosis >50%, angina, CHF, arrhythmia, PVD, CVD or cor pulmonale) | 584 | Nicotine patch | 10 | 6 | 21 for 6 weeks; 14 for 2 weeks; 7 for 2 weeks | Expired CO |
Rigotti et al (31), 2006 | Acute CVD (patients admitted with MI or unstable angina, CABG or other cardiovascular conditions with documented CAD) | 247 | Bupropion | 12 | 12 | 300* | Saliva cotinine |
Campbell et al (36), 1991 | In-hospital CVD patients† | 85 | Nicotine gum | NR‡ | 12 | 2§ | Expired CO |
Taken as 150 mg twice daily;
Called heart disease in the study, not specified further. Patients with other smoking-related diseases were included (total n=219);
Median duration of gum use was 37 days;
Stronger gum (4 mg) was offered for up to 3 months to those still smoking. CABG Coronary artery bypass graft surgery; CHF Congestive heart failure; CO Carbon monoxide; CVD Cardiovascular disease; MI Myocardial infarction; NR Not reported; PVD Peripheral vascular disease